<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263090</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 19-2243</org_study_id>
    <nct_id>NCT04263090</nct_id>
  </id_info>
  <brief_title>Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment</brief_title>
  <official_title>A Phase1/2a Study of Rigosertib Plus Nivolumab in Stage IV Lung Adenocarcinoma Patients With KRAS Mutation Who Progressed on First-Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onconova Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with&#xD;
      KRAS Mutation who Progressed on First-Line Treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, dose-escalating Phase I study followed by a Phase 2a dose-expansion&#xD;
      phase to study the combination of Rigosertib and Nivolumab in metastatic Kirsten rat sarcoma&#xD;
      positive (KRAS+) lung adenocarcinoma patients who have progressed on standard first line&#xD;
      treatment. Study patients will have satisfied the inclusion/exclusion criteria enumerated in&#xD;
      this protocol. The Phase I dose escalation plan will start with an accelerated titration&#xD;
      design (ATD) using single patient cohorts until grade 2 toxicity is experienced. At that&#xD;
      point, the ATD will be terminated and the dose escalation will enter a standard 3+3 design&#xD;
      based on dose-limiting toxicities (DLT). The MTD (Phase 1 primary endpoint) is defined as the&#xD;
      highest dose for which at most 1 patient out of 6 experiences a DLT.&#xD;
&#xD;
      Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2:&#xD;
      560mg in the morning (qAM), 280mg in the evening (qPM); dose D3: 560mg twice daily; taken by&#xD;
      mouth for 21 consecutive days of the 28 day cycle), based on previous dose escalation studies&#xD;
      in other malignancies, while Nivolumab dose will be fixed at the standard dose (240mg every 2&#xD;
      weeks, given intravenously).&#xD;
&#xD;
      Once the MTD is determined, an additional planned 12 patients will be enrolled in the&#xD;
      expansion phase to further study toxicity and to determine preliminary efficacy endpoints&#xD;
      including ORR (phase 2a primary endpoint), PFS, and OS (secondary endpoints) of the&#xD;
      combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose-escalating Phase I study followed by a Phase 2a dose-expansion phase.&#xD;
Rigosertib escalation will occur with three dose levels: Dose D1: 280mg twice daily, Dose D2: 560mg qAM, 280mg qPM, Dose D3: 560mg twice daily. Nivolumab will be dosed at the standard fixed dose of 240mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD)</measure>
    <time_frame>DLTs will be evaluated at the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>MTD is defined as the highest dose for which at most 1 patient out of 6 experiences a dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR is defined as achieving an objective response of either complete response or partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2: PFS is defined as the duration of time from start of treatment to the first occurrence of disease progression or death on study from any cause, whichever occurs earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at MTD</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2: OS at MTD is defined as the time from the first dose of study treatment to the date of death (whatever the cause).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Stage IV</condition>
  <arm_group>
    <arm_group_label>Rigosertib + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rigosertib</intervention_name>
    <description>Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).</description>
    <arm_group_label>Rigosertib + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).</description>
    <arm_group_label>Rigosertib + Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          -  Be at least 18 years of age on the day of signing informed consent.&#xD;
&#xD;
          -  Have a histologically or cytologically confirmed diagnosis of Stage IV metastatic lung&#xD;
             adenocarcinoma (AJCC version 8) with mutation analysis by next generation sequencing&#xD;
             (NGS) confirming KRAS mutation either at time of diagnosis or at progression on first&#xD;
             line treatment.&#xD;
&#xD;
          -  Have progressed on or intolerant of standard of care first-line treatment with&#xD;
             anti-programmed death-ligand 1 (PD1) checkpoint inhibitor monotherapy or anti-PD1&#xD;
             checkpoint inhibitor in combination with platinum doublet chemotherapy for Stage IV&#xD;
             metastatic lung adenocarcinoma. The last cycle of first-line treatment must occur at&#xD;
             least 28 days prior to administration of trial drugs (i.e., washout period)&#xD;
&#xD;
          -  Have measurable disease per RECIST 1.1 as assessed by the local site&#xD;
             investigator/radiology. Lesions situated in a previously irradiated area are&#xD;
             considered measurable if progression has been demonstrated in such lesion.&#xD;
&#xD;
          -  Have a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.&#xD;
&#xD;
          -  Have adequate organ function as indicated by the following laboratory values in Table&#xD;
             1. Specimens must be collected within 14 days prior to the start of trial.&#xD;
&#xD;
          -  Patient must be willing and able to provide blood samples (12 green tops tubes,&#xD;
             roughly 100mL) at the time points indicated in the Study Calendar.&#xD;
&#xD;
          -  Patient must be willing and able to have core needle biopsies (Goal 4-8 biopsies,&#xD;
             final number to be determined by the surgeon and radiologist performing the procedure&#xD;
             as safe) of tumor prior to initiation of study drug, and at time points indicated in&#xD;
             the Study Calendar.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             prior to study entry, for the duration of study participation, and following&#xD;
             completion of therapy for 5 months if female and 7 months if male.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must have a negative serum pregnancy test&#xD;
             within 72 hours prior to receiving the first dose of study drug. Should a woman become&#xD;
             pregnant or suspect she is pregnant while participating in this study, she should&#xD;
             inform her treating physician immediately. A female of child-bearing potential is any&#xD;
             woman (regardless of sexual orientation, having undergone a tubal ligation, or&#xD;
             remaining celibate by choice) who meets the following criteria: Has not undergone a&#xD;
             hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for&#xD;
             at least 12 consecutive months (i.e., has had menses at any time in the preceding 12&#xD;
             consecutive months).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents. If received as part of&#xD;
             first line treatment, last administration of previous investigational agent must be&#xD;
             greater than 4 weeks prior to administration of study drug combination.&#xD;
&#xD;
          -  Patients must not be pregnant or nursing due to the potential for congenital&#xD;
             abnormalities or harm to nursing infants.&#xD;
&#xD;
          -  Tumor harbors an epidermal growth factor receptor (EGFR) sensitizing (activating)&#xD;
             mutation or an anaplastic lymphoma kinase (ALK) translocation. All other co-mutations&#xD;
             will be allowed.&#xD;
&#xD;
          -  Has known untreated central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             they are without evidence of progression for at least 4 weeks by repeat radiological&#xD;
             imaging, clinically stable, and without requirement of steroid treatment for at least&#xD;
             14 days prior to first dose of study drug.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment. Patients on chronic steroids (more than 4 weeks at stable dose) equivalent&#xD;
             to â‰¤ 10mg prednisone will not be excluded.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 1 year&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is acceptable.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing and/or required active treatment&#xD;
             within the past 3 years. Exceptions include basal cell carcinoma of the skin or&#xD;
             squamous cell carcinoma of the skin that has undergone potentially curative therapy or&#xD;
             in situ cervical or anal cancer, prostate cancer on stable dose of hormonal therapy&#xD;
             without rising prostate-specific antigen (PSA), and breast cancer whom have been&#xD;
             treated with curative intent, who may be on hormonal therapy.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the patient's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating Investigator.&#xD;
&#xD;
          -  HIV positive with detectable viral load, or anyone not on stable anti-viral (HAART)&#xD;
             regimen, or with &lt;350 cluster of differentiation 4 (CD4+) T cells/microliter in the&#xD;
             peripheral blood. No HIV testing is required.&#xD;
&#xD;
          -  History of allogeneic hematopoietic cell transplantation or solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Receipt of a live vaccine within 30 days of planned start of study medication&#xD;
&#xD;
          -  History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing&#xD;
             pneumonia) or active, noninfectious pneumonitis that required immunosuppressive doses&#xD;
             of glucocorticoids to assist with management. A history of radiation pneumonitis in&#xD;
             the radiation field is permitted.&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated.&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either psychiatric or physical&#xD;
             (e.g. infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajwanth Veluswamy, MD, MSCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajwanth Veluswamy, MD, MSCR</last_name>
    <phone>(212) 824-8580</phone>
    <email>rajwanth.veluswamy@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph LaValle, BA</last_name>
    <phone>2128247376</phone>
    <email>joseph.lavalle@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajwanth Veluswamy, MD, MSCR</last_name>
      <phone>212-824-8580</phone>
      <email>rajwanth.veluswamy@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph LaValle, BA</last_name>
      <phone>2128247376</phone>
      <email>joseph.lavalle@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajwanth Veluswamy, MD, MSCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Rajwanth Veluswamy</investigator_full_name>
    <investigator_title>Assistant Professor, Hematology &amp; Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>KRAS</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Rigosertib</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>ON 01910</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.To achieve aims in the approved proposal.Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link to be included).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

